Clinical trial
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally…
NCT00239304 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00239304 |
|---|---|
| Title | Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer |
| Official title | A Phase I/II Trial of ZD1839 (Iressa) Given Concurrently With Cisplatin and Radiotherapy in Patients With Locally Advanced Head and Neck Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Neoplasms |
| Intervention type | Drug, Procedure |
| Interventions | Gefitinib, Cisplatin, Radiotherapy |
| Enrollment | 40 |
| Start date | Jun 1, 2003 |
| Completion | Mar 1, 2006 |
| First posted | Oct 17, 2005 |
| Last update posted | Dec 18, 2007 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: